Stockreport

COSCIENS Biopharma Inc. Reports Third Quarter 2024 Financial Results and Provides Update on Advancements with Merger Integration Process and Ongoing Development Programs

COSCIENS Biopharma Inc.  (CSCI) 
PDF Continued execution on merger integration with Ceapro Inc. and advancements across business Company ended the quarter with US$20.0 million in cash [Read more]